# Breast Cancer Treatment Studies

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/breast-cancer-treatment-studies/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on molecular research, treatment response, and prognostic markers in breast cancer. It covers topics such as gene expression patterns, molecular subtypes, neoadjuvant therapy, radiotherapy, and the impact of hormone receptors on survival. The papers also discuss the development of clinical practice guidelines for breast cancer management. |
| Domain | Life Sciences |
| Field | Biochemistry, Genetics and Molecular Biology |
| OpenAlex ID | t10183 |
| Works | 804 |

## Topic papers all

Showing 15 of 804.

- [Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2](https://scholariq.org/papers/use-of-chemotherapy-plus-a-monoclonal-antibody-against-her2-for-metastatic/)
- [Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications](https://scholariq.org/papers/gene-expression-patterns-of-breast-carcinomas-distinguish-tumor-subclasses-with/)
- [A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer](https://scholariq.org/papers/a-multigene-assay-to-predict-recurrence-of-tamoxifen-treated-node-negative/)
- [Twenty-Year Follow-up of a Randomized Trial Comparing Total Mastectomy, Lumpectomy, and Lumpectomy plus Irradiation for the Treatment of Invasive Breast Cancer](https://scholariq.org/papers/twenty-year-follow-up-of-a-randomized-trial-comparing-total-mastectomy/)
- [Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study](https://scholariq.org/papers/tamoxifen-for-prevention-of-breast-cancer-report-of-the-national-surgical/)
- [Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer](https://scholariq.org/papers/trastuzumab-plus-adjuvant-chemotherapy-for-operable-her2-positive-breast-cancer/)
- [Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials](https://scholariq.org/papers/effects-of-radiotherapy-and-of-differences-in-the-extent-of-surgery-for-early/)
- [Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer](https://scholariq.org/papers/trastuzumab-after-adjuvant-chemotherapy-in-her2-positive-breast-cancer/)
- [Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis](https://scholariq.org/papers/pathological-complete-response-and-long-term-clinical-benefit-in-breast-cancer/)
- [Triple-Negative Breast Cancer](https://scholariq.org/papers/triple-negative-breast-cancer/)
- [Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials](https://scholariq.org/papers/effect-of-radiotherapy-after-breast-conserving-surgery-on-10-year-recurrence-and/)
- [Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study](https://scholariq.org/papers/race-breast-cancer-subtypes-and-survival-in-the-carolina-breast-cancer-study/)
- [Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013](https://scholariq.org/papers/personalizing-the-treatment-of-women-with-early-breast-cancer-highlights-of-the/)
- [Pembrolizumab for Early Triple-Negative Breast Cancer](https://scholariq.org/papers/pembrolizumab-for-early-triple-negative-breast-cancer/)
- [Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer](https://scholariq.org/papers/paclitaxel-plus-bevacizumab-versus-paclitaxel-alone-for-metastatic-breast-cancer/)

## Topic primary papers

Showing 15 of 385.

- [A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer](https://scholariq.org/papers/a-multigene-assay-to-predict-recurrence-of-tamoxifen-treated-node-negative/)
- [Twenty-Year Follow-up of a Randomized Trial Comparing Total Mastectomy, Lumpectomy, and Lumpectomy plus Irradiation for the Treatment of Invasive Breast Cancer](https://scholariq.org/papers/twenty-year-follow-up-of-a-randomized-trial-comparing-total-mastectomy/)
- [Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study](https://scholariq.org/papers/tamoxifen-for-prevention-of-breast-cancer-report-of-the-national-surgical/)
- [Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials](https://scholariq.org/papers/effects-of-radiotherapy-and-of-differences-in-the-extent-of-surgery-for-early/)
- [Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis](https://scholariq.org/papers/pathological-complete-response-and-long-term-clinical-benefit-in-breast-cancer/)
- [Triple-Negative Breast Cancer](https://scholariq.org/papers/triple-negative-breast-cancer/)
- [Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials](https://scholariq.org/papers/effect-of-radiotherapy-after-breast-conserving-surgery-on-10-year-recurrence-and/)
- [Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study](https://scholariq.org/papers/race-breast-cancer-subtypes-and-survival-in-the-carolina-breast-cancer-study/)
- [Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013](https://scholariq.org/papers/personalizing-the-treatment-of-women-with-early-breast-cancer-highlights-of-the/)
- [Pembrolizumab for Early Triple-Negative Breast Cancer](https://scholariq.org/papers/pembrolizumab-for-early-triple-negative-breast-cancer/)
- [Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer](https://scholariq.org/papers/response-to-neoadjuvant-therapy-and-long-term-survival-in-patients-with-triple/)
- [Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes](https://scholariq.org/papers/definition-and-impact-of-pathologic-complete-response-on-prognosis-after/)
- [Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer](https://scholariq.org/papers/gene-expression-and-benefit-of-chemotherapy-in-women-with-node-negative-estrogen/)
- [American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer](https://scholariq.org/papers/american-society-of-clinical-oncology-2007-update-of-recommendations-for-the-use/)
- [Five-Year Results of a Randomized Clinical Trial Comparing Total Mastectomy and Segmental Mastectomy with or without Radiation in the Treatment of Breast Cancer](https://scholariq.org/papers/five-year-results-of-a-randomized-clinical-trial-comparing-total-mastectomy-and/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.